Baicalein tethers CD274/PD-L1 for autophagic degradation to boost antitumor immunity

被引:0
|
作者
Hao, Bingjie [1 ,2 ]
Lin, Shumeng [1 ,2 ]
Liu, Haipeng [3 ]
Xu, Junfang [3 ]
Chen, Li [3 ]
Zheng, Tiansheng [2 ]
Zhang, Wen [2 ]
Dang, Yifang [4 ]
Reiter, Russel J. [5 ]
Li, Chaoqun [1 ]
Zhai, Hong [2 ]
Xia, Qing [1 ]
Fan, Lihong [1 ,2 ,6 ]
机构
[1] Tongji Univ, Shanghai Peoples Hosp 10, Inst Energy Metab & Hlth, Sch Med, Shanghai, Peoples R China
[2] Tongji Univ, Shanghai Peoples Hosp 10, Sch Med, Dept Resp Med, Shanghai 200072, Peoples R China
[3] Tongji Univ, Shanghai Pulm Hosp, Clin Translat Res Ctr, Sch Med, Shanghai, Peoples R China
[4] Tongji Univ, Shanghai Pulm Hosp, Sch Med, Shanghai, Peoples R China
[5] Univ Texas Hlth San Antonio, Dept Cell Syst & Anat, San Antonio, TX USA
[6] Shanghai Jiao Tong Univ, Sch Med, Dept Resp Med, Shanghai Peoples Hosp 6, Shanghai, Peoples R China
基金
中国国家自然科学基金;
关键词
Antitumor immunity; autophagy; baicalein; CD274; MAP1LC3B; protein degradation; LYSOSOMAL DEGRADATION; PD-L1; ANTI-PD-1; BLOCKADE; PROTEINS; COMPLEX; TARGET;
D O I
10.1080/15548627.2024.2439657
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Immune checkpoint inhibitors, especially those targeting CD274/PD-L1yield powerful clinical therapeutic efficacy. Thoughmuch progress has been made in the development of antibody-basedCD274 drugs, chemical compounds applied for CD274degradation remain largely unavailable. Herein,baicalein, a monomer of traditional Chinese medicine, isscreened and validated to target CD274 and induces itsmacroautophagic/autophagic degradation. Moreover, we demonstrate thatCD274 directly interacts with MAP1LC3B (microtubule associatedprotein 1 light chain 3 beta). Intriguingly, baicalein potentiatesCD274-LC3 interaction to facilitate autophagic-lysosomal degradationof CD274. Importantly, targeted CD274. degradation via baicaleininhibits tumor development by boosting T-cell-mediated antitumorimmunity. Thus, we elucidate a critical role of autophagy-lysosomalpathway in mediating CD274 degradation, and conceptually demonstratethat the design of a molecular "glue" that tethers the CD274-LC3interaction is an appealing strategy to develop CD274 inhibitors incancer therapy.Abbreviations: ATTECs: autophagy-tethering compounds; AUTACs: AUtophagy-TArgeting Chimeras; AUTOTACs: AUTOphagy-TArgeting Chimeras; AMPK: adenosine 5'-monophosphate (AMP)-activated protein kinase; BiFC: bimolecular fluorescence complementation; BafA1: bafilomycin A1; CD274/PD-L1/B7-H1: CD274 molecule; CQ: chloroquine; CGAS: cyclic GMP-AMP synthase; DAPI: 4'6-diamino-2-phenylindole; FITC: fluorescein isothiocyanate isomer; GFP: green fluorescent protein; GZMB: granzyme B; IHC: immunohistochemistry; ICB: immune checkpoint blockade; KO: knockout; KD: equilibrium dissociation constant; LYTAC: LYsosome-TArgeting Chimera; LIR: LC3-interacting region; MAP1LC3/LC3: microtubule associated protein 1 light chain 3; MST: microscale thermophoresis; NFAT: nuclear factor of activated T cells; NFKB/NF-kB: nuclear factor kappa B; NSCLC: non-small-cell lung cancer; PDCD1: programmed cell death 1; PROTACs: PROteolysis TArgeting Chimeras; PRF1: perforin 1; PE: phosphatidylethanolamine; PHA: phytohemagglutinin; PMA: phorbol 12-myristate 13-acetate; STAT: signal transducer and activator of transcription; SPR: surface plasmon resonance; TILs: tumor-infiltrating lymphocyte; TME: tumor microenvironment.
引用
收藏
页数:17
相关论文
共 50 条
  • [41] Expression of ALCAM (CD166) and PD-L1 (CD274) independently predicts shorter survival in malignant pleural mesothelioma
    Inaguma, Shingo
    Lasota, Jerzy
    Wang, Zengfeng
    Czapiewski, Piotr
    Langfort, Renata
    Rys, Janusz
    Szpor, Joanna
    Waloszczyk, Piotr
    Okon, Krzysztof
    Biernat, Wojciech
    Ikeda, Hiroshi
    Schrump, David S.
    Hassan, Raffit
    Miettinen, Markku
    HUMAN PATHOLOGY, 2018, 71 : 1 - 7
  • [42] Repurposing screen identifies Amlodipine as an inducer of PD-L1 degradation and antitumor immunity
    Li, Chushu
    Yao, Han
    Wang, Huanbin
    Fang, Jing-Yuan
    Xu, Jie
    ONCOGENE, 2021, 40 (06) : 1128 - 1146
  • [43] Repurposing screen identifies Amlodipine as an inducer of PD-L1 degradation and antitumor immunity
    Chushu Li
    Han Yao
    Huanbin Wang
    Jing-Yuan Fang
    Jie Xu
    Oncogene, 2021, 40 : 1128 - 1146
  • [44] Canagliflozin primes antitumor immunity by triggering PD-L1 degradation in endocytic recycling
    Ding, Ling
    Chen, Xi
    Zhang, Wenxin
    Dai, Xiaoyang
    Guo, Hongjie
    Pan, Xiaohui
    Xu, Yanjun
    Feng, Jianguo
    Yuan, Meng
    Gao, Xiaomeng
    Wang, Jian
    Xu, Xiaqing
    Li, Sicheng
    Wu, Honghai
    Cao, Ji
    He, Qiaojun
    Yang, Bo
    JOURNAL OF CLINICAL INVESTIGATION, 2023, 133 (01):
  • [45] TIME (Tumor Immunity in the MicroEnvironment) classification based on tumor CD274 (PD-L1) expression status and tumor-infiltrating lymphocytes in colorectal carcinomas
    Hamada, Tsuyoshi
    Soong, Thing Rinda
    Masugi, Yohei
    Kosumi, Keisuke
    Nowak, Jonathan A.
    da Silva, Annacarolina
    Mu, Xinmeng Jasmine
    Twombly, Tyler S.
    Koh, Hideo
    Yang, Juhong
    Song, Mingyang
    Liu, Li
    Gu, Mancang
    Shi, Yan
    Nosho, Katsuhiko
    Morikawa, Teppei
    Inamura, Kentaro
    Shukla, Sachet A.
    Wu, Catherine J.
    Garraway, Levi A.
    Zhang, Xuehong
    Wu, Kana
    Meyerhardt, Jeffrey A.
    Chan, Andrew T.
    Glickman, Jonathan N.
    Rodig, Scott J.
    Freeman, Gordon J.
    Fuchs, Charles S.
    Nishihara, Reiko
    Giannakis, Marios
    Ogino, Shuji
    ONCOIMMUNOLOGY, 2018, 7 (07):
  • [46] Different Induction of PD-L1 (CD274) and PD-1 (CD279) Expression in THP-1-Differentiated Types 1 and 2 Macrophages
    Lai, Chun-Yi
    Tseng, Po-Chun
    Chen, Chia-Ling
    Satria, Rahmat Dani
    Wang, Yung-Ting
    Lin, Chiou-Feng
    JOURNAL OF INFLAMMATION RESEARCH, 2021, 14 : 5241 - 5249
  • [47] Pan-cancer analysis of CD274 (PD-L1) mutations in 314,631 patient samples and subset correlation with PD-L1 protein expression.
    Huang, Richard S. P.
    Decker, Brennan
    Murugesan, Karthikeyan
    Hiemenz, Matthew
    Mata, Douglas A.
    Li, Gerald
    Creeden, James
    Ramkissoon, Shakti H.
    Ross, Jeffrey S.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [48] The Expression Level of PD-L1 (CD274) mRNA in Peripheral Blood Is a Potential Biomarker for Predicting Recurrence in Breast Cancer
    Masuda, Takaaki
    Noda, Miwa
    Kitagawa, Akihiro
    Hu, Qingjiang
    Fujii, Atsushi
    Ito, Shuhei
    Kosai, Keisuke
    Ando, Yuki
    Matsumoto, Yoshihiro
    Ohtsu, Hajime
    Uchida, Hiroki
    Ohno, Shinji
    Mimori, Koshi
    ANTICANCER RESEARCH, 2020, 40 (07) : 3733 - 3742
  • [49] Amplifications of PD-L1(CD274) and PD-L2 (PDCD1LG2) in a Large Cohort of Solid Tumors and Hematologic Malignancies
    Wang, K.
    Johnson, A.
    Ali, S. M.
    Yelensky, R.
    Balko, J.
    Lipson, D.
    Elvin, J. A.
    Vergilio, J.
    Hawryluk, M.
    Miller, V. A.
    Stephens, P. J.
    Ross, J. S.
    JOURNAL OF MOLECULAR DIAGNOSTICS, 2015, 17 (06): : 802 - 802
  • [50] The Role of Programmed Cell Death Ligand-1 (PD-L1/CD274) in the Development of Graft versus Host Disease
    Al-Chaqmaqchi, Heevy
    Sadeghi, Behnam
    Abedi-Valugerdi, Manuchehr
    Al-Hashmi, Sulaiman
    Fares, Mona
    Kuiper, Raoul
    Lundahl, Joachim
    Hassan, Moustapha
    Moshfegh, Ali
    PLOS ONE, 2013, 8 (04):